Xiao-Jie Ouyang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiao-Jie Ouyang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chenyi Wu
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, P. R. China
16 shared publications - Feng Wang
Sun Yat-sen University Cancer Center 1 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China
16 shared publications - Jiajia Hu
Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer Chinese Academy of Medical Sciences Guangzhou People's Republic of China
16 shared publications - Jiaying Chen
Department of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center For Cancer Sun Yat‐Sen University Cancer Center Sun Yat‐Sen University Guangzhou People's Republic of China
16 shared publications - Jinling Zhang
Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer Chinese Academy of Medical Sciences Guangzhou People's Republic of China
16 shared publications - Lin Tian
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
16 shared publications
Latest Publications
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Immunotherapy has made remarkable strides in the treatment of solid tumors, but its efficacy as a single agent in immunologically cold tumors remains limited. Therefore, it is necessary to explore novel drug combinations to further optimize immunotherapy. Herein, we demonstrated that the histone deacetylase inhibitor (HDACi) chidamide enhanced chromatin accessibility at the promoters of genes that encode effector molecules in CD8+ T cells, thereby augmenting their antitumor capabilities. However, HDACi also induced the expression of VEGFA in protumorigenic macrophages, which led to vascular abnormalization and hindered immune cell infiltration, compromising its potential synergistic effect with immunotherapy. Accordingly, combining antiangiogenic therapy counteracted the angiogenic effects of HDACi, collaboratively unleashing the infiltration and functionality of cytotoxic CD8+ T cells. These findings were confirmed by single-cell RNA sequencing data from our patient samples. Thus, through mechanistic research, we propose a new therapeutic approach by the combination of HDACi, antiangiogenic therapy, and immunotherapy, highlighting its potential application across diverse solid tumors.Significance:The challenges of tumor therapy primarily lie in developing novel intervention strategies to shift the tumor microenvironment toward an antitumor phenotype. Herein, we discovered that the combination of HDACi and antiangiogenic therapy promoted the functionality and infiltration of CD8+ T cells, ultimately remodeling the tumor microenvironment and boosting immunotherapy efficacy.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Immunotherapy has made remarkable strides in the treatment of solid tumors, but its efficacy as a single agent in immunologically cold tumors remains limited. Therefore, it is necessary to explore novel drug combinations to further optimize immunotherapy. Herein, we demonstrated that the histone deacetylase inhibitor (HDACi) chidamide enhanced chromatin accessibility at the promoters of genes that encode effector molecules in CD8+ T cells, thereby augmenting their antitumor capabilities. However, HDACi also induced the expression of VEGFA in protumorigenic macrophages, which led to vascular abnormalization and hindered immune cell infiltration, compromising its potential synergistic effect with immunotherapy. Accordingly, combining antiangiogenic therapy counteracted the angiogenic effects of HDACi, collaboratively unleashing the infiltration and functionality of cytotoxic CD8+ T cells. These findings were confirmed by single-cell RNA sequencing data from our patient samples. Thus, through mechanistic research, we propose a new therapeutic approach by the combination of HDACi, antiangiogenic therapy, and immunotherapy, highlighting its potential application across diverse solid tumors.Significance:The challenges of tumor therapy primarily lie in developing novel intervention strategies to shift the tumor microenvironment toward an antitumor phenotype. Herein, we discovered that the combination of HDACi and antiangiogenic therapy promoted the functionality and infiltration of CD8+ T cells, ultimately remodeling the tumor microenvironment and boosting immunotherapy efficacy.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The video of 3D images in tumor tissues treated with CP regimen
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The video of 3D images in tumor tissues treated with CP regimen
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor hinders the infiltration of CD8+ T cells
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor hinders the infiltration of CD8+ T cells
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The gating strategy of main cell types and T cells through flow cytometry in this article
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The gating strategy of main cell types and T cells through flow cytometry in this article
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor promotes the expression of VEGFa in macrophage
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
HDAC inhibitor promotes the expression of VEGFa in macrophage
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Vascular abnormalization is associated with the efficacy of HDAC inhibitor combined immunotherapy
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Vascular abnormalization is associated with the efficacy of HDAC inhibitor combined immunotherapy
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The information about the patients and primers used in this article
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The information about the patients and primers used in this article
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The video of 3D images in tumor tissues treated with P regimen
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The video of 3D images in tumor tissues treated with P regimen
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The toxicity of Combined HDAC inhibitor with anti-angiogenesis therapy
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
The toxicity of Combined HDAC inhibitor with anti-angiogenesis therapy
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Combined HDAC inhibitor, anti-angiogenesis therapy with immunotherapy hastens the immune cells infiltration and functionality in patient sample
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
Combined HDAC inhibitor, anti-angiogenesis therapy with immunotherapy hastens the immune cells infiltration and functionality in patient sample